Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news


From To
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide

After three years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir

27 March 2017
Liz Highleyman
Darunavir Associated with Heart Disease

But atazanavir use in HIV patients not linked to cardiovascular disease.

20 February 2017
MedPage Today HIV/AIDS
Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study

16 February 2017
Carole Leach-Lemens
How a gene test can solve side effects linked to ARV drugs in Africa

Studies have shown that people who react particularly badly to efavirenz have a particular gene variant that messes with an enzyme responsible for processing the drug in their bodies.

01 February 2017
The Conversation
High prevalence of low testosterone among younger and middle-aged ART-treated men in France

Around one in six young and middle-aged HIV-positive men doing well on antiretroviral therapy (ART) had low testosterone levels, French investigators report in the online edition of

24 January 2017
Michael Carter
Top 10 HIV Clinical Developments of 2016

In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

02 December 2016
The Body Pro
Efavirenz Side Effects Include Suicide; It Could Have Been Me

I was on efavirenz for years. Within six months of dropping the drug altogether, I normalized. For the first time in years, I was not flooded with suicidal thoughts, addictions and crippling mental health woes.

31 October 2016
The Body
The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears

The 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) heard today that over a 20-year period, people who suffered lipodystrophy (fat redistribution) and

26 October 2016
Gus Cairns
Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk

Insomnia, dizziness, headache and other central nervous system side-effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to

25 October 2016
Keith Alcorn
Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate

Almost one in seven people in a Dutch clinic population stopped treatment with the HIV integrase inhibitor dolutegravir because of side-effects, investigators from the Netherlands report in

13 October 2016
Michael Carter
← First12345...76Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.